Storia in 3 fonti

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics aims to secure ₹200 crore to enhance its capital expenditures through a new issuance of shares. In tandem, the firm intends to reduce promoter stake by generating ₹740 crore via an offer for sale. With six manufacturing sites worldwide, the company caters to over ninety nations and has seen substantial revenue growth attributed to its tuberculosis diagnostic test kits.

Raccontata da

thehindubusinessline.com

economictimes.indiatimes.com

m.economictimes.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.comStai leggendo5 g fa

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics IPO raises ₹940 crore; revenue +31.5% over two years, net profit +40.2%, P/E ~57. TB kit dependency (70% revenue) and customer concentration (>50%) present risk; Truenat platform's 90-country reach and 22.6% EBITDA margins provide resilience.

originale

m.economictimes.com4 g fa

Molbio Diagnostics IPO opens: Should you subscribe for Rs 940 crore issue?

Market analysts have recommended subscribing to the issue, noting that Molbio Diagnostics valuations are broadly in line with industry benchmarks. The company is also being offered at a discount to the average P/E…

Timeline cronologica

sabato 8 agosto 2026·thehindubusinessline.com
Molbio Diagnostics raises ₹281 cr from anchor investors ahead of IPO
Molbio Diagnostics raises ₹281.5 crore from anchor investors ahead of its IPO, set to open for subscription on August 10.
sabato 8 agosto 2026·economictimes.indiatimes.com
Molbio Diagnostics collects Rs 281 cr from anchor investors ahead of IPO
Molbio Diagnostics has successfully attracted Rs 281.5 crore from anchor investors ahead of its much-anticipated initial public offering. The company aims to raise between Rs 904…

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Confronto fonti

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics IPO opens: Should you subscribe for Rs 940 crore issue?

Timeline cronologica

Molbio Diagnostics raises ₹281 cr from anchor investors ahead of IPO

Molbio Diagnostics collects Rs 281 cr from anchor investors ahead of IPO

Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day

Molbio IPO: Should Investors Subscribe?

World Bank's IFC, HDFC AMC invest in Molbio Diagnostics' Rs 281 crore IPO anchor round

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics IPO: Analyst recommendations—should you subscribe or give it a miss?

Molbio Diagnostics IPO opens: Should you subscribe for Rs 940 crore issue?

Molbio Diagnostics IPO opens today: GMP at 15% — Check price band. Should you subscribe?

Molbio IPO Day 2: GMP hits at 17% listing gains. Should you bid?

Screening India’s healthcare diagnostics market

Molbio Diagnostics IPO Day 3: GMP hints at 17% listing gain, issue booked nearly 5x. Should you participate?

Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day